Share:
OTTAWA, ON / ACCESSWIRE / April 28, 2021 /
Tetra Bio-Pharma Inc. (
Tetra or the
Company ) (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development announced today that it has submitted a request to the Malta Medicines Authority for a Scientific Opinion on its investigational new drug (IND) QIXLEEF for Tetra s clinical trial programs. This request includes guidance on the REBORN2 trial to be performed in Europe. QIXLEEF is a botanical drug product with a fixed ratio of THC and CBD and is inhaled through a vaporizer. Based on the speed of onset of the pharmacodynamic effects of QIXLEEF, Tetra has positioned this inhaled IND as a potential therapy for the rapid relief of severe acute pain, such as breakthrough pain. Patients require fast relief when suffering from excruciating pain and we believe that the fast onset of QIXLEEF might be a viable alternative to opioids. We are seeking guidance from the Malta Medicines Authority on
Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.
Tetra Bio-Pharma Submits Request for Scientific Advice to Malta Medicines Authority
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Tetra Bio-Pharma Provides an Update on its U.S. REBORN1 Clinical Trial
Tetra completes manufacturing of QIXLEEF clinical trial drug for REBORN1 trial
Export permit received from Health Canada for immediate shipping to USA
OTTAWA, ON / ACCESSWIRE / April 23, 2021 /
Tetra Bio-Pharma Inc. (
Tetra or the
Company ) (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a leader in cannabinoid-derived drug discovery and development is pleased to announce that it has shipped the investigational new drug, QIXLEEF, to the USA for the initiation of the REBORN1 study. The Company has completed the manufacturing of QIXLEEF and has received the cannabis export permit from Health Canada. REBORN1 will investigate cannabis as an alternative to morphine sulfate immediate release in the management of breakthrough pain. QIXLEEF is a botanical drug product with a fixed ratio of THC and CBD and is inhaled through a vaporizer.
Press release content from Accesswire. The AP news staff was not involved in its creation.
Tetra Bio-Pharma Announces Granting of U.S. Patent for Treatment of Interstitial Cystitis
April 15, 2021 GMT
Approximately 12% of women may have early symptoms of Interstitial Cystitis
OTTAWA, ON / ACCESSWIRE / April 15, 2021 / Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) ( TSX:TBP )( OTCQB:TBPMF )( FRA:JAM1 ), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces the granting of a new patent from the United States Patent and Trademark Office for patent application number 16/190,450. This patent covers a method for the treatment of interstitial cystitis.
ADVERTISEMENT
Interstitial cystitis (IC), also known as bladder pain syndrome, is a chronic bladder health issue. According to the Interstitial Cystitis Association, approximately 4 to 12 million people in the U.S. are subject to IC, and approximately 90% of the IC patients are women. Epidemio